Palatin Technologies, Inc.(NYSE Amex Equities : PTN)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||2.23%||8.71||0.7%||$608.86m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.20%||651.88||2.7%||$494.43m|
|GILD||Gilead Sciences, Inc.||0.39%||71.61||1.0%||$434.34m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.64%||188.30||1.9%||$241.59m|
|ISEE||IVERIC bio, Inc.||1.59%||16.62||0.0%||$194.78m|
|LIFE||aTyr Pharma, Inc.||0.49%||10.31||3.2%||$144.19m|
|EXAS||EXACT Sciences Corp.||5.22%||108.15||18.1%||$135.69m|
Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, a peptide melanocortin receptor 4 agonist for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.